Björn Löwenadler

Arexis AB develops and manufactures pharmaceutical products. Its products are used for molecular dissection of metabolic and inflammatory diseases. The company was founded in 1999 and is headquartered in Goteborg, Sweden.

Prokarium Holdings Ltd. provides management services. The private company is based in London, UK. The British company was founded in 2014. Kristen Albright has been the CEO of the company since 2018.

Bohus BioTech AB is a Swedish company that manufactures and develops hyaluronic acid products. The company is based in Stromstad, Sweden and has subsidiaries in Sweden. The company was founded in 1992 by Daniel C. Ogbonnaya.

NorthX Biologics Matfors AB is a biologics company that specializes in high-quality protein production and DNA manufacturing. The company is based in Matfors, Sweden, and has subsidiaries in Sweden. The Swedish company offers comprehensive cell banking services, including master cell bank production, GMP cell banking, and cell bank characterization, ensuring quality and compliance for biological products. The company also provides premium plasmid DNA services, offering GMP, High Quality, and Research Grade plasmids for gene therapy, cell therapy, molecular biology research, and clinical applications. The company was founded in 1963, and Janet Hoogstraate has been the CEO of the company since 2023.

Prokarium Ltd. operates as a biopharmaceutical company that focuses on developing vaccination solutions based on synthetic biology. Its oral vaccine delivery platform Vaxonella stimulates broad protective immune responses applicable to a wide range of diseases. The company is headquartered in Keele, the United Kingdom.

Part of Recipharm AB, Consort Medical GmbH is a German company that functions as an investment holding company. The company is based in Monheim, Germany. The CEO of the company is Thomas Bengt Eldered.

Pierre Fabre SA is a holding company which engages in the research, development, and production of health and beauty product based on natural and biological active ingredients. It operates through the following divisions: Pharmaceutical, Consumer Health Care, and Dermo-Cosmetics. The Pharmaceutial division focuses on therapeutic products for oncology, urology, women’s health, neuropsychiatry, cardiology, pulmonology, allergology, and rheumatology. The Consumer Health division includes prescription over-the-counter drugs which covers family health, oral care, and natural health care. The Dermo-Cosmetics division comprises skin and hair care products. The company was founded by Pierre Fabre in 1962 and is headquartered in Paris, France.

Buzzard Pharmaceuticals AB develops oncology drugs. The company is based in Stockholm, Sweden. The Swedish company was founded by Urban Paulsson. The CEO is Maarten de Château.

Part of Recipharm AB, Recipharm Fontaine SAS is a French pharmaceutical company that manufactures pharmaceutical products. The company is based in Fontaine-les-Dijon, France. The company was founded in 2008. Pascal Prudent has been the CEO of the company since 2017.

Part of Recipharm AB, Recipharm Monts SAS is a company that manufactures sterile injectable anesthetic products. The company is based in Monts, France. Carl Ericson has been the CEO of the French company since 2019.

Aesica Formulation Development Ltd. develops pharmaceutical products. It offers sterile and nutraceutical product development and drug delivery services. The company was founded on December 22, 2005 and is headquartered in Northumberland, the United Kingdom.

Flerie Participation AB is an investment holding Swedish company. The company is based in Stockholm, Sweden.

Part of Recipharm AB, Aesica Holdco Ltd. operates as a holding British company. The company is based in Hemel Hempstead, UK.

C. D. S. GmbH provides catering services. The private company is based in Reichertshofen, Germany. The CEO of the German company is Lorenz Weichselbaumer.

Oncorena Holding AB develops novel pharmacological treatment for metastatic renal clear cell cancer. It conducts clinical trial for potential new therapies. The company was founded by Björn Oskar Larsson in 2011 and is headquartered in Helsingborg, Sweden.

Sobrera Pharma AB manufactures pharmaceutical products for patients with alcohol use disorders. The company is based in Gothenburg, Sweden. The CEO of the Swedish company is Ann-Charlotte Rosendahl.

MetaboGen AB operates a metagenome and metabolic disease platform. It provides commercial access to metagenome research and development. The firm offers create next generation probiotics and pharmaceutical products, based on the microbiome. The company was founded in 2011 and is headquartered in Göteborg, Sweden.

Recipharm Holdings Ltd. operates from a multipurpose manufacturing facility, The company was founded on August 10, 2012 and is headquartered in Ashton-Under-Lyne, the United Kingdom.

Gypius AB provides support services for artistic activities. The private company is based in Gothenburg, Sweden.

SymCel AB develops and markets analytical instrumentations for cell biological research and development. Its products include calScreener, calPlate System, and calView date collection and analysis software. The company was founded by Dan Rolf Stefan Hallen and Bertil Ingemar Wadso in 2004 and is headquartered in Spanga, Sweden.

Part of Recipharm AB, Recipharm Verwaltungs GmbH is an investment holding German company. The company is based in Wasserburg am Inn, Germany. The CEOs of the company are Michael Isele, Thomas Bengt Eldered.

Amarna Therapeutics BV operates as a biotechnology company developing SVac viral gene delivery vector platform. The firm has developed a proprietary SuperVero cell line and SVec gene delivery platform for the development of safe and efficient immunotherapies for major indications within the degenerative, inflammatory and autoimmune disease areas. The company was founded by Ben van Leent and Peter de Haan in 2008 and is headquartered in Leiden, the Netherlands.

Novartis Sverige AB trades pharmaceutical products. It offers products for the treatment of ADHD, multiple sclerosis, urticaria, allergic asthma, psoriasis, chronic obstructive pulmonary disorder, migraine, blood diseases, eye disorder, and other diseases. The company is headquartered in Kista, Sweden.

KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel.